PT  - JOURNAL ARTICLE
AU  - Young-Xu, Yinong
AU  - Zwain, Gabrielle M.
AU  - Izurieta, Hector S.
AU  - Korves, Caroline
AU  - Powell, Ethan I.
AU  - Smith, Jeremy
AU  - Balajee, Abirami S.
AU  - Holodniy, Mark
AU  - Beenhouwer, David O.
AU  - Rodriguez-Barradas, Maria C.
AU  - Brown, Sheldon T.
AU  - Marconi, Vincent C.
TI  - Effectiveness of mRNA COVID-19 Booster Vaccines against Omicron and Delta Variants among US Veterans
AID  - 10.1101/2022.01.15.22269360
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.15.22269360
4099  - http://medrxiv.org/content/early/2022/03/13/2022.01.15.22269360.short
4100  - http://medrxiv.org/content/early/2022/03/13/2022.01.15.22269360.full
AB  - Background We estimated vaccine effectiveness (VE) of mRNA vaccines among US Veterans during periods of Delta and Omicron variant dominance. Patients included in this study were largely 65 years or older (62,834, 55%), male (101,259, 88%), and non-Hispanic white (66,986, 58%).Methods We used SARS-CoV-2 laboratory test results to conduct a matched test-negative case-control study to estimate VE of three and two doses of mRNA vaccines against infection (regardless of symptoms), and a matched case-control study to estimate VE against COVID-19-related hospitalization and death. We estimated VE as (1-odds ratio) x 100%. Severity of disease was measured using hospital length of stay (LOS) and admission to an intensive care unit (ICU).Results Against infection, booster doses had 7-times higher VE - 59% (95% confidence interval [CI], 57 to 61) - than 2-dose VE (7%; 95% CI, 3 to 10) during the Omicron period. For the Delta period, estimated VE against infection was 90% (95% CI, 88 to 92) among boosted vaccinees, 64% higher than VE among 2-dose vaccinees [55% (95% CI, 51 to 58)]. Against hospitalization, booster dose VE was 87% (95% CI, 80 to 91) during Omicron and 95% (95% CI, 91 to 97) during Delta; the 2-dose VE was 44% (95% CI, 26 to 58) during Omicron and 75% (95% CI, 70 to 80) during Delta. Against death, estimated VE with a booster dose was 94% (95% CI, 85 to 98) during Omicron and 96% (95% CI, 88 to 99) during Delta, while the 2-dose VE was 75% (95% CI, 52 to 87) during Omicron and 93% (95% CI, 85 to 97) during Delta. During the Omicron period, average hospital LOS was 4 days shorter [3 days (95%CI, 3 to 4 days)] than during the Delta period.Conclusions A mRNA vaccine booster is more effective against infection, hospitalization, and death than 2-dose vaccination among an older male population with comorbidities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by both the U.S. Food and Drug Administration and the U.S. Department of Veterans Affairs (VA) Office of Rural Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review board of the Department of Veterans Affairs Medical Center in White River Junction, Vermont, and was granted an exemption for consent because it was deemed impractical.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available upon request to: Clinical Epidemiology Program Veterans Affairs Medical Center 215 North Main Street White River Junction, VT 05009